It is well known that the development of a new drug is exorbitantly expensive and is a process which usually fails. Researchers at PrecisionLife posit that failure and the many patients with unmet treatment needs result from an over simplistic view of disease pathogeneses and an overreliance on a narrow range of target genes and pathways.

At the European Hematology Association's annual meeting in Vienna last week, companies reported impressive progress for the treatment of sickle cell disease.